Adding bicalutamide to salvage radiotherapy improves OS in recurrent prostate cancer

Adding antiandrogen therapy with bicalutamide to salvage radiotherapy significantly improved long-term survival and reduced the risk of metastatic disease compared with radiation treatment alone in patients with recurrent prostate cancer, a study published in The New England Journal of Medicine has shown.
Oncology Nurse Advisor